Patients with septicemia or severe infection
164.0
Patients with septicemia or severe infection
360.0
Active systemic infection or skin infection at or near the acupuncture sites
240.0
PROCUREMENT: Patients with severe intercurrent infection
44.0
TREATMENT: Patients with severe intercurrent infection
44.0
A second malignancy requiring active therapy
40.0
Patients with evidence of active septicemia, severe infection, gastrointestinal bleeding or severe gastrointestinal symptoms requiring medical or surgical therapy
52.0
Patients should not have any evidence of active or uncontrolled infection requiring treatment with antibiotics
45.0
Patients should not have any clinical evidence of an active infection at the time of enrollment
55.0
Patients with a previous or current line infection are ineligible until 14 days after the completion of antibiotics
450.0
Clinically active infection; an active infection may alter the biodistribution of 18F-FLT
75.0
Active bacterial or fungal infection; all prior infections must be resolved following optimal therapy
12.0
Acute treatment for an infection (excluding fungal infection of the skin and sexually transmitted infections) or other serious medical illness within 14 days prior to randomization
150.0
Patients must not have any incidence of or uncontrolled medical illness (e.g. active cardiac symptoms, active systemic infection, etc.) that would limit the patient�s ability to participate in the protocol
230.0
Uncontrolled intercurrent illness including active infection
57.0
Acute treatment for an infection (excluding fungal infection of the skin and sexually transmitted infections) or other serious medical illness within 2 weeks before Segment B enrollment
56.0
Active lung infection
75.0
Concurrent, acute, active infection, or treatment for infection, other than oral thrush or genital herpes, within 14 days of enrollment
42.0
Active infection or chronic infection requiring chronic suppressive antibiotics
990.0
Infection requiring systemic antibiotic therapy or other serious infection within 14 days before registration
110.0
Opportunistic infection within the last 3 months
84.0
Ongoing or active infection; treatment with systemic antibiotics or antifungals for ongoing or recurrent infection (topical use of antibiotics or antifungals is allowed)
23.0
Symptomatic/active bacterial, or fungal, or any other opportunistic infection
18.0
Patients must not have any incidence of or uncontrolled medical illness (e.g. active cardiac symptoms, active systemic infection, etc.) that would limit the patient�s ability to participate in the protocol
333.0
Active infection
48.0
Active or chronic infection requiring systemic therapy
348.0
Patients must not have a serious intercurrent illness, including ongoing or active infection requiring parental antibiotics
766.0
Patients must not have an active infection requiring systemic therapy
77.0
Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration.
186.0
Patients must not have an active infection requiring oral or IV antibiotics within 14 days prior to registration; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible
148.0
Severe and/or symptomatic refractory concurrent infection other than EBV
90.0
Patients who have an active uncontrolled infection defined as: * Positive bacterial blood culture within 48 hours of study enrollment; * Fever above 38.2 degree Celsius (C) within 48 hours of study enrollment with clinical signs of infection; fever that is determined to be due to tumor burden is allowed if patients have documented negative blood cultures for at least 48 hours prior to enrollment and no concurrent signs or symptoms of active infection or hemodynamic instability* A positive fungal culture within 30 days of study enrollment or active therapy for presumed invasive fungal infection* Patients may be receiving IV or oral antibiotics to complete a course of therapy for a prior documented infection as long as cultures have been negative for at least 48 hours and signs or symptoms of active infection have resolved; for patients with clostridium (c.) difficile diarrhea, at least 72 hours of antibacterial therapy must have elapsed and stools must have normalized to baseline* Active viral or protozoal infection requiring IV treatment
53.0
Active, uncontrolled infection, or active systemic illness that requires ongoing vasopressor support or mechanical ventilation
700.0
Patients must not have an active infection requiring systemic therapy
1000.0
Patients must not have an active infection requiring systemic therapy nor a viral infection requiring intermittent treatment with an antiherpetic drug, other than intermittent topical use
64.0
Patients must not have an active infection requiring systemic therapy at time of registration
94.0
